卖什么
mRNA therapeutics to extend healthspan entering clinical trials
商业模式拆解
买家：谁掌握预算？
未核实Eventual payers: health systems/insurers via drug approval; near-term funders are investors and grant agencies.
工作流：什么输入变成什么输出？
Proprietary therapeutic telomere extension (mRNA) to lengthen telomeres in specific cells; claims 5+ years of telomere shortening reversed in 1 day in cells; targeting diseases such as pulmonary fibrosis, liver disease and bone marrow failure.
经济账：省了什么，怎么收费？
Pre-revenue biotech funded by equity and grants: claims over $8M in grant funding awarded since 2023 and over 40 patents granted.
渠道：怎么接触到客户？
未核实Therapeutic pipeline route: clinical trials then regulatory approval and likely pharma partnering; no commercial channel yet.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2018 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.